Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02983461 · ClinicalTrials.gov registry record · Phase 1
Use of Sildenafil for Treatment of Urinary Incontinence
A Phase 1 study of Urinary Incontinence, sponsored by The University of Texas Medical Branch, Galveston.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02983461: Active Phase 1 study of Urinary Incontinence, sponsored by The University of Texas Medical Branch, Galveston.
NCT02983461 is a Phase 1 study of Urinary Incontinence that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 24 participants, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02983461, a Phase 1 study of Urinary Incontinence, is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators goal is to develop medical treatments for stress/mixed urinary incontinence. Sildenafil has been shown to improve blood flow as well as muscle mass and strength and to decrease muscle fatigue. The investigators believe that it will improve muscular atrophy in the pelvic floor, thus improving symptoms of urinary incontinence related to pelvic floor dysfunction.
Primary Outcome
Pad tests quantitatively measures urine leakage
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sildenafil
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What the registry record for NCT02983461 still lists
NCT02983461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02983461 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02983461 about?
NCT02983461 is a clinical study titled "Use of Sildenafil for Treatment of Urinary Incontinence". The investigators goal is to develop medical treatments for stress/mixed urinary incontinence. Sildenafil has been shown to improve blood flow as well as muscle mass and strength and to decrease muscle fatigue. The investigators believe that it will improve muscular atrophy in the pelvic floor, thus...
What is the current status of trial NCT02983461?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-03-10. Estimated completion is 2027-07.
What conditions does trial NCT02983461 study?
This clinical trial studies the following conditions: Urinary Incontinence.
What interventions are being tested in trial NCT02983461?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT02983461?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02983461 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02983461's enrollment target sits among peer trials
24 39th of 48 higher than 9 of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Muscle Fiber Fragment Treatment for Urinary Incontinence
RECRUITING · Phase 1
-
Muscle Progenitor Cell Therapy for Urinary Incontinence
COMPLETED · Phase 1
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI